NMS-P715 is the first selective, ATP-competitive and orally bioavailable MPS1 small-molecule inhibitor (IC50=8 nM) and selectively reduces cancer cell proliferation, leaving normal cells almost unaffected.

CC-671 is a selective inhibitor of TTK (Mps1) and CLK2 with IC50s of 5 nM and 3 nM, respectively.

BAY1217389 is a potent, and selective inhibitor of the monopolar spindle 1 (MPS1) kinase with an IC50 value less than 10 nM.

BOS172722 is clinical candidate Mps1 inhibitor with IC50 value of 11nM.

Mps1-IN-3 is a selective and highly potent MPS1 kinase inhibitor with an IC50 of 50 nM.

CFI-402257 is a novel and selective Mps1 inhibitor with Ki value of 0.1 nM.

BAY 1161909 inhibits Mps1 kinase activity with IC50 of < 1 nM when assay with 10 μM ATP, with IC50 of < 1.9 nM when assay with 2 mM ATP.

AZ3146 is a selective and potent Mps1 inhibitor with IC50 value of 35 nM.

MPI-0479605 is a potent and selective ATP competitive Mps1 with IC50 value of 1.8 nM.

Mps1-IN-2 is a potent Mps1 kianse inhibitor with IC50 value of 145 nM.

1,16-Hexadecanediol is a plant wax derivative. It could activate Mps1 MAP kinase pathway.

TC-Mps1-12 is a potent and selective monopolar spindle 1 (Mps1) inhibitor.

Mps1-IN-1 dihydrochloride is a potent, selective and ATP-competitive Mps1 kinase inhibitor, with an IC50 and a Kd of 367 nM and 27 nM[1].

Mps1-IN-1 is a highly potent and selectibe Mpsl inhibitor with IC50 of 367 nM, displaying > 1000-fold selectivity relative to the 352 member kinase panel with the major exceptions of Alk and Ltk.